Cardium Reports on Recent Highlights and Financi...(nical study and announce top line ...),Health

safety and efficacy data for Excellarate.

-- Continue patient recruitment in our Phase 3 AWARE clinical study for

Generx, which is expected to be completed in 2009.

-- Secure FDA clearance for InnerCool's next-generation RapidBlue

endovascular cooling system.

-- Accelerate the commercialization of InnerCool's surface and

endovascular temperature modulation systems in the U.S..

-- Conduct additional pre-clinical studies supported by Tissue Repair's

SBIR grant to evaluate Corgentin as a potential one-time biologic

treatment for heart attack patients.

-- Continue to consider opportunistic acquisitions of innovative product

candidates, and evaluate potential sales or strategic partnering

opportunities for existing products and candidates.

Cardium also reported that the audit opinion accompanying its consolidated financial statements for the year ended December 31, 2007, which statements were included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 14, 2008, contained a going concern qualification from its independent registered public accounting firm, Marcum & Kliegman LLP. Consistent with its business strategy, Cardium plans to raise additional funds through the strategic sale or monetization of its operating units, entering into strategic licensing agreements, and/or as appropriate, may also consider the sale of securities in registered direct transactions under its effective shelf registration statement.

This announcement is made in compliance with Section 610(b) of the American Stock Exchange Company Guide, which requires listed companies to make a public announcement of the receipt of an audit opinion that contains a going concern qualification. This announcement does not reflect any change or amendment to the consolidated financial statements as filed. Mo
'/>"/>